JP2013532668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532668A5 JP2013532668A5 JP2013520993A JP2013520993A JP2013532668A5 JP 2013532668 A5 JP2013532668 A5 JP 2013532668A5 JP 2013520993 A JP2013520993 A JP 2013520993A JP 2013520993 A JP2013520993 A JP 2013520993A JP 2013532668 A5 JP2013532668 A5 JP 2013532668A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- ethyl
- methylamino
- substituted methylene
- monosubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 48
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 28
- 239000012453 solvate Substances 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 230000001419 dependent effect Effects 0.000 claims 11
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 10
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- -1 methyl-substituted methylene Chemical group 0.000 claims 5
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000011066 hemangioma Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 230000005747 tumor angiogenesis Effects 0.000 claims 2
- FLGUGRAWIWHCJF-MRXNPFEDSA-N 2-ethyl-4-[[(1s)-1-(3-fluorophenyl)-2-(methylamino)ethyl]amino]quinazoline-8-carboxamide Chemical compound C1([C@@H](CNC)NC=2N=C(N=C3C(C(N)=O)=CC=CC3=2)CC)=CC=CC(F)=C1 FLGUGRAWIWHCJF-MRXNPFEDSA-N 0.000 claims 1
- SKSIVYGMKXKZAL-MRXNPFEDSA-N 2-ethyl-4-[[(1s)-1-(4-fluorophenyl)-2-(methylamino)ethyl]amino]quinazoline-8-carboxamide Chemical compound C1([C@@H](CNC)NC=2N=C(N=C3C(C(N)=O)=CC=CC3=2)CC)=CC=C(F)C=C1 SKSIVYGMKXKZAL-MRXNPFEDSA-N 0.000 claims 1
- DMIFTASZHIOFDS-MRXNPFEDSA-N 2-ethyl-4-[[(1s)-2-(methylamino)-1-phenylethyl]amino]quinazoline-8-carboxamide Chemical compound C1([C@@H](CNC)NC=2N=C(N=C3C(C(N)=O)=CC=CC3=2)CC)=CC=CC=C1 DMIFTASZHIOFDS-MRXNPFEDSA-N 0.000 claims 1
- POFQBVKRYMOMRR-MRXNPFEDSA-N 2-methyl-4-[[(1s)-2-(methylamino)-1-phenylethyl]amino]quinazoline-8-carboxamide Chemical compound C1([C@H](NC=2C3=CC=CC(=C3N=C(C)N=2)C(N)=O)CNC)=CC=CC=C1 POFQBVKRYMOMRR-MRXNPFEDSA-N 0.000 claims 1
- KDWHIHJILMZLQT-MRXNPFEDSA-N 4-[(2s)-3-(azetidin-1-yl)-2-(3-chlorophenyl)propyl]-2-ethylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)CC)C=1C=C(Cl)C=CC=1)N1CCC1 KDWHIHJILMZLQT-MRXNPFEDSA-N 0.000 claims 1
- GICHDAPJTGXHJB-MRXNPFEDSA-N 4-[(2s)-3-(azetidin-1-yl)-2-(3-chlorophenyl)propyl]-2-methylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)C)C=1C=C(Cl)C=CC=1)N1CCC1 GICHDAPJTGXHJB-MRXNPFEDSA-N 0.000 claims 1
- DVDSKHYUBCNSOF-MRXNPFEDSA-N 4-[(2s)-3-(azetidin-1-yl)-2-(3-fluorophenyl)propyl]-2-ethylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)CC)C=1C=C(F)C=CC=1)N1CCC1 DVDSKHYUBCNSOF-MRXNPFEDSA-N 0.000 claims 1
- FNHYSUBXBFOTCI-MRXNPFEDSA-N 4-[(2s)-3-(azetidin-1-yl)-2-(3-fluorophenyl)propyl]-2-methylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)C)C=1C=C(F)C=CC=1)N1CCC1 FNHYSUBXBFOTCI-MRXNPFEDSA-N 0.000 claims 1
- LJTQGHLIYHSMOX-MRXNPFEDSA-N 4-[(2s)-3-(azetidin-1-yl)-2-(4-chlorophenyl)propyl]-2-ethylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)CC)C=1C=CC(Cl)=CC=1)N1CCC1 LJTQGHLIYHSMOX-MRXNPFEDSA-N 0.000 claims 1
- LPMREZWHAIEKQZ-MRXNPFEDSA-N 4-[(2s)-3-(azetidin-1-yl)-2-(4-chlorophenyl)propyl]-2-methylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)C)C=1C=CC(Cl)=CC=1)N1CCC1 LPMREZWHAIEKQZ-MRXNPFEDSA-N 0.000 claims 1
- TVXPEQKGAHYKQO-MRXNPFEDSA-N 4-[(2s)-3-(azetidin-1-yl)-2-(4-fluorophenyl)propyl]-2-ethylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)CC)C=1C=CC(F)=CC=1)N1CCC1 TVXPEQKGAHYKQO-MRXNPFEDSA-N 0.000 claims 1
- OSVXDIAAYFUGBW-MRXNPFEDSA-N 4-[(2s)-3-(azetidin-1-yl)-2-(4-fluorophenyl)propyl]-2-methylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)C)C=1C=CC(F)=CC=1)N1CCC1 OSVXDIAAYFUGBW-MRXNPFEDSA-N 0.000 claims 1
- PSVWDJSMYZACCK-QGZVFWFLSA-N 4-[(2s)-3-(azetidin-1-yl)-2-phenylpropyl]-2-ethylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)CC)C=1C=CC=CC=1)N1CCC1 PSVWDJSMYZACCK-QGZVFWFLSA-N 0.000 claims 1
- KVZQADFWZCYYQV-QGZVFWFLSA-N 4-[(2s)-3-(azetidin-1-yl)-2-phenylpropyl]-2-methylquinazoline-8-carboxamide Chemical compound C([C@@H](CC=1N=C(N=C2C(C(N)=O)=CC=CC2=1)C)C=1C=CC=CC=1)N1CCC1 KVZQADFWZCYYQV-QGZVFWFLSA-N 0.000 claims 1
- GZSKSABPMQXDBI-MRXNPFEDSA-N 4-[[(1s)-1-(3-chlorophenyl)-2-(methylamino)ethyl]amino]-2-ethylquinazoline-8-carboxamide Chemical compound C1([C@@H](CNC)NC=2N=C(N=C3C(C(N)=O)=CC=CC3=2)CC)=CC=CC(Cl)=C1 GZSKSABPMQXDBI-MRXNPFEDSA-N 0.000 claims 1
- TUGQXVDVBAIMQT-MRXNPFEDSA-N 4-[[(1s)-1-(3-chlorophenyl)-2-(methylamino)ethyl]amino]-2-methylquinazoline-8-carboxamide Chemical compound C1([C@H](NC=2C3=CC=CC(=C3N=C(C)N=2)C(N)=O)CNC)=CC=CC(Cl)=C1 TUGQXVDVBAIMQT-MRXNPFEDSA-N 0.000 claims 1
- GDZSUVPAQIUIGI-CQSZACIVSA-N 4-[[(1s)-1-(3-fluorophenyl)-2-(methylamino)ethyl]amino]-2-(trifluoromethyl)quinazoline-8-carboxamide Chemical compound C1([C@H](NC=2C3=CC=CC(=C3N=C(N=2)C(F)(F)F)C(N)=O)CNC)=CC=CC(F)=C1 GDZSUVPAQIUIGI-CQSZACIVSA-N 0.000 claims 1
- DSLKQMBMFBKGRK-MRXNPFEDSA-N 4-[[(1s)-1-(3-fluorophenyl)-2-(methylamino)ethyl]amino]-2-methylquinazoline-8-carboxamide Chemical compound C1([C@H](NC=2C3=CC=CC(=C3N=C(C)N=2)C(N)=O)CNC)=CC=CC(F)=C1 DSLKQMBMFBKGRK-MRXNPFEDSA-N 0.000 claims 1
- NMCWJLCHHFXWFC-MRXNPFEDSA-N 4-[[(1s)-1-(4-chlorophenyl)-2-(methylamino)ethyl]amino]-2-ethylquinazoline-8-carboxamide Chemical compound C1([C@@H](CNC)NC=2N=C(N=C3C(C(N)=O)=CC=CC3=2)CC)=CC=C(Cl)C=C1 NMCWJLCHHFXWFC-MRXNPFEDSA-N 0.000 claims 1
- NDQZVNOJBBXGOJ-MRXNPFEDSA-N 4-[[(1s)-1-(4-chlorophenyl)-2-(methylamino)ethyl]amino]-2-methylquinazoline-8-carboxamide Chemical compound C1([C@H](NC=2C3=CC=CC(=C3N=C(C)N=2)C(N)=O)CNC)=CC=C(Cl)C=C1 NDQZVNOJBBXGOJ-MRXNPFEDSA-N 0.000 claims 1
- PYWWWUCMNVNQOM-QGZVFWFLSA-N 4-[[(1s)-1-(4-chlorophenyl)-2-(methylamino)ethyl]amino]-2-propan-2-ylquinazoline-8-carboxamide Chemical compound C1([C@H](NC=2C3=CC=CC(=C3N=C(N=2)C(C)C)C(N)=O)CNC)=CC=C(Cl)C=C1 PYWWWUCMNVNQOM-QGZVFWFLSA-N 0.000 claims 1
- SWJLPMOSDVXEPJ-MRXNPFEDSA-N 4-[[(1s)-1-(4-fluorophenyl)-2-(methylamino)ethyl]amino]-2-methylquinazoline-8-carboxamide Chemical compound C1([C@H](NC=2C3=CC=CC(=C3N=C(C)N=2)C(N)=O)CNC)=CC=C(F)C=C1 SWJLPMOSDVXEPJ-MRXNPFEDSA-N 0.000 claims 1
- 125000000815 N-oxide group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36896410P | 2010-07-29 | 2010-07-29 | |
| US61/368,964 | 2010-07-29 | ||
| PCT/EP2011/003272 WO2012013282A1 (en) | 2010-07-29 | 2011-07-01 | Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532668A JP2013532668A (ja) | 2013-08-19 |
| JP2013532668A5 true JP2013532668A5 (enExample) | 2014-08-14 |
| JP5894157B2 JP5894157B2 (ja) | 2016-03-23 |
Family
ID=44532723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520993A Expired - Fee Related JP5894157B2 (ja) | 2010-07-29 | 2011-07-01 | キナーゼｐ７０Ｓ６Ｋの阻害剤としての二環式アザ複素環式カルボキサミド |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8710044B2 (enExample) |
| EP (1) | EP2598492B1 (enExample) |
| JP (1) | JP5894157B2 (enExample) |
| KR (1) | KR101852644B1 (enExample) |
| CN (1) | CN103003250B (enExample) |
| AR (1) | AR082414A1 (enExample) |
| AU (1) | AU2011285247B2 (enExample) |
| BR (1) | BR112013002090A2 (enExample) |
| CA (1) | CA2806610C (enExample) |
| CL (1) | CL2013000263A1 (enExample) |
| EA (1) | EA023132B1 (enExample) |
| ES (1) | ES2557383T3 (enExample) |
| IL (1) | IL224072A (enExample) |
| MX (1) | MX2013001054A (enExample) |
| NZ (1) | NZ604379A (enExample) |
| SG (1) | SG187166A1 (enExample) |
| UA (1) | UA110113C2 (enExample) |
| WO (1) | WO2012013282A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| MX342288B (es) | 2010-04-22 | 2016-09-23 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
| WO2012016001A1 (en) * | 2010-07-29 | 2012-02-02 | Merck Patent Gmbh | Cyclic amine azaheterocyclic carboxamides |
| CA2818706C (en) * | 2010-11-24 | 2019-07-23 | Merck Patent Gmbh | Quinazoline carboxamide azetidines |
| ES2644536T3 (es) | 2011-09-12 | 2017-11-29 | Merck Patent Gmbh | Imidazol-aminas novedosas como moduladores de la actividad cinasa |
| JP6082011B2 (ja) | 2011-09-12 | 2017-02-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | キナーゼ活性のモジュレーターとして使用するためのアミノピリミジン誘導体 |
| ES2807539T3 (es) | 2012-11-16 | 2021-02-23 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa |
| ES2620119T3 (es) | 2012-11-16 | 2017-06-27 | Merck Patent Gmbh | Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa |
| ES2821102T3 (es) * | 2012-11-29 | 2021-04-23 | Merck Patent Gmbh | Derivados de azaquinazolincarboxamida |
| AR095202A1 (es) | 2013-03-11 | 2015-09-30 | Merck Patent Gmbh | Heterociclos como moduladores de la actividad quinasa |
| CN103232401B (zh) * | 2013-04-12 | 2015-11-04 | 浙江工业大学 | 一种4-芳硫基喹唑啉类化合物的合成方法 |
| CN103254141B (zh) * | 2013-04-26 | 2016-02-24 | 浙江工业大学 | 4-[4-(2-二丙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用 |
| KR102410696B1 (ko) | 2014-04-03 | 2022-06-17 | 메르크 파텐트 게엠베하 | 암 치료법의 조합 |
| KR102447581B1 (ko) | 2014-04-15 | 2022-09-28 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물 |
| US20230220395A1 (en) * | 2020-04-21 | 2023-07-13 | University Of Massachusetts | Methods and compositions for treatment of age-related macular degeneration |
| MX2023005520A (es) | 2020-11-16 | 2023-05-23 | Merck Patent Gmbh | Combinaciones de inhibidores de cinasa para tratamiento de cancer. |
| WO2023039068A1 (en) * | 2021-09-08 | 2023-03-16 | Neubase Therapeutics, Inc. | Compositions and methods for synthesis of peptide nucleic acid intermediates |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| WO2001083456A1 (en) * | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Condensed heteroaryl derivatives |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| WO2004014873A1 (ja) * | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| WO2004014861A1 (ja) * | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キノリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| JP2006522124A (ja) | 2003-04-03 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用な組成物 |
| JP2007507531A (ja) | 2003-09-30 | 2007-03-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| JP4800216B2 (ja) | 2003-10-24 | 2011-10-26 | エグゼリクシス， インコーポレイテッド | ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法 |
| KR20060117329A (ko) | 2003-11-21 | 2006-11-16 | 노파르티스 아게 | 단백질 키나제 저해제로서의 1ｈ-이미다조퀴놀린 유도체 |
| US8044057B2 (en) | 2003-12-09 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for suppressing an immune response or treating a proliferative disorder |
| AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| EP1781293A1 (en) | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| WO2006071819A1 (en) | 2004-12-28 | 2006-07-06 | Exelixis, Inc. | [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2006136821A1 (en) | 2005-06-22 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical compounds |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| CN102317269B (zh) * | 2009-02-11 | 2015-06-17 | 默克专利有限公司 | 新氨基氮杂杂环甲酰胺类 |
-
2011
- 2011-01-07 UA UAA201302432A patent/UA110113C2/uk unknown
- 2011-07-01 KR KR1020137005466A patent/KR101852644B1/ko not_active Expired - Fee Related
- 2011-07-01 MX MX2013001054A patent/MX2013001054A/es active IP Right Grant
- 2011-07-01 BR BR112013002090A patent/BR112013002090A2/pt active Search and Examination
- 2011-07-01 CA CA2806610A patent/CA2806610C/en active Active
- 2011-07-01 NZ NZ604379A patent/NZ604379A/en not_active IP Right Cessation
- 2011-07-01 EA EA201300186A patent/EA023132B1/ru not_active IP Right Cessation
- 2011-07-01 WO PCT/EP2011/003272 patent/WO2012013282A1/en not_active Ceased
- 2011-07-01 US US13/703,276 patent/US8710044B2/en active Active
- 2011-07-01 SG SG2013004965A patent/SG187166A1/en unknown
- 2011-07-01 CN CN201180037284.6A patent/CN103003250B/zh not_active Expired - Fee Related
- 2011-07-01 ES ES11738160.8T patent/ES2557383T3/es active Active
- 2011-07-01 AU AU2011285247A patent/AU2011285247B2/en not_active Ceased
- 2011-07-01 EP EP11738160.8A patent/EP2598492B1/en active Active
- 2011-07-01 JP JP2013520993A patent/JP5894157B2/ja not_active Expired - Fee Related
- 2011-07-29 AR ARP110102741A patent/AR082414A1/es active IP Right Grant
-
2012
- 2012-12-31 IL IL224072A patent/IL224072A/en active IP Right Grant
-
2013
- 2013-01-28 CL CL2013000263A patent/CL2013000263A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532668A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2012517470A5 (enExample) | ||
| JP2017511794A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2014518266A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| RU2014131065A (ru) | Димерные соединения-агонисты рецептора fgf ( fgfr ), способ их получения и их терапевтическое применение | |
| JP2015508749A5 (enExample) | ||
| WO2008076415A1 (en) | Methods of using mek inhibitors | |
| JP2014516360A5 (enExample) | ||
| JP2011509949A5 (enExample) | ||
| RU2012112050A (ru) | Производные дигидроптеридинона, способ их получения и фармацевтическое применение | |
| EP4467549A3 (en) | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives | |
| JP2008540554A5 (enExample) | ||
| JP2011509301A5 (enExample) | ||
| FI3681857T3 (fi) | Fluorifenyyli-beeta-hydroksietyyliamiineja ja niiden käyttö hyperglykaemian hoidossa | |
| IL256646A (en) | History of azaquinazoline carboxamide, their preparation and pharmaceutical preparations containing them | |
| HRP20160044T1 (hr) | Novi spojevi fenilamino izonikotinamida |